Holen Sie sich die Stockscreener-App
11.63
0.95%
0.11
Handel nachbörslich:
11.61
-0.02
-0.17%
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals Holding Corp at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Millennium group reports 890,366 shares (5.6%) in Tonix (TNXP) - Stock Titan
Tonix Pharmaceuticals director Taylor buys $14,928 in stock By Investing.com - Investing.com South Africa
Insider Buying: Carolyn Taylor Acquires Shares of Tonix Pharmace - GuruFocus
Director Carolyn Taylor buys Tonix Pharmaceuticals (TNXP) shares in open market - Stock Titan
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 15.76% to 55.42 - MSN
We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate - Yahoo Finance
Tonix Pharmaceuticals Holding Corp (TNXP) Stock Price, Quote, News & History - Benzinga
Tonix Pharmaceuticals Holding Corp. Trade Ideas — TRADEGATE:TPM0 - TradingView
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 - marketscreener.com
(TNXP) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tonix CEO Seth Lederman buys $58,949 in company stock By Investing.com - Investing.com Canada
Insider Buying: Richard Stillwell Acquires Shares of Tonix Pharm - GuruFocus
Tonix Pharmaceuticals director Stillwell buys $58,250 in shares By Investing.com - Investing.com Canada
Tonix CEO Seth Lederman buys $58,949 in company stock - Investing.com UK
Tonix Pharmaceuticals director Stillwell buys $58,250 in shares - Investing.com
[Form 4] Tonix Pharmaceuticals Holding Corp. Insider Trading Activity - Stock Titan
Tonix (NASDAQ: TNXP) CEO Lederman acquires 5,000 shares in open-market buy - Stock Titan
Tonix Pharmaceuticals (TNXP) Expands Tonmya Coverage to 17 Milli - GuruFocus
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Blue Owl Capital (OBDC) Regains Ground: Modest Gain Signals Stability Near Key LevelsBearish Sentiment - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
Tonix Pharmaceuticals Expands TONMYA® Fibromyalgia Coverage to 52 Million Lives with Second Major GPO Agreement - Minichart
Tonix Pharmaceuticals stock gains on expanded TONMYA coverage By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals stock gains on expanded TONMYA coverage - Investing.com
Tonix expands commercial coverage for fibromyalgia drug TONMYA - Investing.com UK
Tonix expands commercial coverage for fibromyalgia drug TONMYA By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals secures GPO coverage for TONMYA, expanding commercial access to ~52M U.S. lives - TradingView
TONMYA coverage reaches 52M U.S. commercial lives under GPO deals (TNXP) - Stock Titan
First new fibromyalgia medicine in over 15 years now covered for 52M people - Stock Titan
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
BTS ARIRANG Exhibition at ARTE Museum Poised to Drive Las Vegas Tourism RevenueUpward Estimate Revision - The Legal Advocate
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
Tonix presents data on opioid use in fibromyalgia patients By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (TNXP) Unveils Findings on Opioid Use in F - GuruFocus
Tonix presents data on opioid use in fibromyalgia patients - Investing.com UK
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting - GlobeNewswire
Bay Area Lyme Foundation Raises $900,000 at LymeAid 2026, Presenting Inaugural Neil L. Spector, MD, Legacy Award and $300,000 in Emerging Leader Grants - GlobeNewswire Inc.
TNXP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tonix Pharmaceuticals (TNXP) Publishes Positive Phase 1 Study Re - GuruFocus
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):